sözaltı news Finance
Finance
EN AZ
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

marketwatch.com 06.11.2026 17:29 34 views
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.

As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future Patients who use Hims & Hers Health's telehealth platform can now directly order Eli Lilly's GLP-1 medications on the site. s Health announced a new arrangement with Eli Lilly that allows patients to purchase the drugmaker’s GLP-1 medications directly through its platform. In the past, patients who participated in Hims’ weight-loss program and wanted to take Zepbound, Lilly’s popular GLP-1 shot, or Foundayo, its new GLP-1 pill, were directed to Lilly’s telehealth platform to purchase the medication. Copyright ©2026 MarketWatch, Inc.

All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8 Jaimy Lee is a healthcare editor and reporter for MarketWatch. She is based in New York. What the governor-elect of Texas, at the epicenter of the AI-trade blowup, is now saying about data centers Here are the 2027 capital-gains tax rates for each income level Cybertruck’s run comes to an end as Musk kills off pricey pet project Americans think they’ll need $5,094 a month to live comfortably in retirement.

Here’s how far off they are from reality. Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET.

All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Extract — continue reading at the source.

Read full story